2018•Journal of the American Academy of DermatologyRequires access

Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study’”

Outi Varpuluoma, Laura Huilaja, Kaisa Tasanen

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Linagliptin, Vildagliptin, Bullous pemphigoid, Medicine, Scopus, Dipeptidyl peptidase-4, Sitagliptin, Dipeptidyl peptidase-4 inhibitor

Back to paper search Browse research topics Original source

Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study’” — Research Paper | ScholarLens